Intravesical Bacille Calmette-Guérin Therapy for Non-Muscle-Invasive Bladder Cancer: Effects of Concurrent Statin Therapy

Journal of the American College of Surgeons

Volumn 209, Issue 2, 2009, Pages 248-253

  Skolarus, Ted A ^a   Lee, Eugene W ^a   Virgo, Katherine S ^b,c   Katz, Matthew D ^a   Hudson, M'Liss A ^a,b   Kibel, Adam S ^a   Grubb III, Robert L ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTRAVESICAL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CYSTECTOMY; DRUG DOSE REDUCTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METASTASIS; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SMOKING;

ADMINISTRATION, INTRAVESICAL; AGED; BCG VACCINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VETERANS;

EID: 67650738582     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2009.04.014     Document Type: Article

References (27)

1. Bohle A., and Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170 (2003) 964-969
2. Brassell S.A., and Kamat A.M. Contemporary intravesical treatment options for urothelial carcinoma of the bladder. J Natl Compr Canc Netw 4 (2006) 1027-1036
3. Ratliff T.L., Ritchey J.K., Yuan J.J., et al. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150 (1993) 1018-1023
4. Soloway M.S. Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37 (1977) 2918-2929
5. Thanhauser A., Bohle A., Flad H.D., et al. Induction of bacillus-Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 37 (1993) 105-111
6. Greenwood J., Steinman L., and Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6 (2006) 358-370
7. Kwak B., Mulhaupt F., Myit S., et al. Statins as a newly recognized type of immunomodulator. Nat Med 6 (2000) 1399-1402
8. Youssef S., Stuve O., Patarroyo J.C., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420 (2002) 78-84
9. Sena A., Pedrosa R., and Graca Morais M. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 250 (2003) 754-755
10. Vollmer T., Key L., Durkalski V., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
11. McCarey D.W., McInnes I.B., Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363 (2004) 2015-2021
12. Berglund R.K., Savage C.J., Vora K.C., et al. An analysis of the effect of statin use on the efficacy of bacillus Calmette-Guerin treatment for transitional cell carcinoma of the bladder. J Urol 180 (2008) 1297-1300
13. Hoffmann P., Roumeguere T., Schulman C., et al. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355 (2006) 2705-2707
14. Kamat A.M., and Wu X. Statins and the effect of BCG on bladder cancer. N Engl J Med 356 (2007) 1276 author reply 1276-1277
15. Kamat A.M., and Nelkin G.M. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66 (2005) 1209-1212
16. Shannon J., Tewoderos S., Garzotto M., et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 162 (2005) 318-325
17. Friis S., Poulsen A.H., Johnsen S.P., et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 114 (2005) 643-647
18. Graaf M.R., Beiderbeck A.B., Egberts A.C., et al. The risk of cancer in users of statins. J Clin Oncol 22 (2004) 2388-2394
19. Sato S., Ajiki W., Kobayashi T., et al. Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 16 (2006) 201-206
20. Setoguchi S., Glynn R.J., Avorn J., et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 115 (2007) 27-33
21. Bonovas S., Filioussi K., Tsavaris N., et al. Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol 24 (2006) 4808-4817
22. Friis S., and Olsen J.H. Statin use and cancer risk: an epidemiologic review. Cancer Invest 24 (2006) 413-424
23. Department of Veterans Affairs (VHA Directive 2003-042) Veterans Health Administration. National smoking and tobacco use cessation program. August 6, 2003. http://www.publichealth.va.gov/documents/VHA_Directive_2003_042.pdf Accessed April 4, 2009
24. Weiss J.S., Dumas P., Cha C., et al. Safety of carotid endarterectomy in a high-risk population: lessons from the VA and Connecticut. J Am Coll Surg 203 (2006) 277-282
25. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
26. Amling C.L. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25 (2001) 219-278
27. Tsai H.K., Katz M.S., Coen J.J., et al. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. Urology 68 (2006) 1188-1192